Table 1.
Fifty most cited articles in nail psoriasis
| Rank | Title | Design | Total citations |
|---|---|---|---|
| 1 | Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–12 | Survey | 337 |
|
| |||
| 2 | Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27 | CME | 266 |
|
| |||
| 3 | Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, Mchugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Rheumatology. 1994;33(9):834–9 | Cohort | 258 |
|
| |||
| 4 | De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, Van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300 | Survey | 230 |
|
| |||
| 5 | Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), mander/newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), maastricht ankylosing spondylitis enthesis score (MASES), leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of Life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res. 2011;63(Suppl 11):S64–85 | Review | 189 |
|
| |||
| 6 | Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis − a high-resolution MRI and histological study. Rheumatology. 2007;46(2):253–6 | Cohort | 179 |
|
| |||
| 7 | Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis − clinically important, potentially treatable and often overlooked. Rheumatology. 2004;43(6):790–4 | Cohort | 147 |
|
| |||
| 8 | Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995;32(1):78–88 | RCT | 136 |
|
| |||
| 9 | Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224–31 | RCT | 135 |
|
| |||
| 10 | Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–5 | Survey | 134 |
|
| |||
| 11 | Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–9 | Cohort | 125 |
|
| |||
| 12 | Zaias N. Psoriasis of the nail: a Clinical-Pathologic Study. Arch Dermatol. 1969;99(5):567–9 | Cohort | 125 |
|
| |||
| 13 | McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):9–13 | Review | 124 |
|
| |||
| 14 | McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage − implications for an improved understanding of the link between psoriasis and arthritis. Dermatology. 2009;218(2):97–102 | Review | 113 |
|
| |||
| 15 | Van Den Bosch F, Manger B, Goupille P, McHugh N, R⊘devand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69(2):394–9 | Cohort | 106 |
|
| |||
| 16 | Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a Prospective Clinical Study. J Cutan Med Surg. 2003;7(4):317–21 | Cohort | 103 |
|
| |||
| 17 | Ash ZR, Tinazzi I, Castillo-Gallego C, Kwok C, Wilson C, Goodfield M, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012;71(4):553–6 | Cohort | 97 |
|
| |||
| 18 | Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–9 | RCT | 95 |
|
| |||
| 19 | Scher RK, Stiller M, Isabel Zhu Y. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–8 | RCT | 91 |
|
| |||
| 20 | Gutierrez M, Wortsman X, Filippucci E, De Angelis R, Filosa G, Grassi W. High-frequency sonography in the evaluation of psoriasis: nail and skin involvement. J Ultrasound Med. 2009;28(11):1569–74 | Cohort | 90 |
|
| |||
| 21 | Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Emery P, Wakefield RJ, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2013;225(3):231–5 | Cohort | 88 |
|
| |||
| 22 | Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269–71 | Cohort | 85 |
|
| |||
| 23 | Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Care Res. 2009;61(9):1235–42 | Survey | 80 |
|
| |||
| 24 | Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–42 | RCT | 79 |
|
| |||
| 25 | Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904 | RCT | 79 |
|
| |||
| 26 | De Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol. 1998;138(1):90–5 | Cohort | 79 |
|
| |||
| 27 | Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(Suppl 1):1–5 | Review | 77 |
|
| |||
| 28 | Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20(1):60–67 | Review | 77 |
|
| |||
| 29 | De Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25(5):357–62 | Review | 77 |
|
| |||
| 30 | Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448–59 | Review | 76 |
|
| |||
| 31 | Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):15–21 | Review | 75 |
|
| |||
| 32 | Wortsman X, Jemec GBE. Ultrasound imaging of nails. Dermatol Clin. 2006;24(3):323–8 | Review | 73 |
|
| |||
| 33 | Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled Study. Dermatology. 2003;206(2):153–6 | RCT | 72 |
|
| |||
| 34 | Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159(2):453–6 | Cohort | 69 |
|
| |||
| 35 | Scarpa R, Soscia E, Peluso R, Atteno M, Manguso F, Del Puente A, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315–9 | Cohort | 69 |
|
| |||
| 36 | Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8 | Cohort | 68 |
|
| |||
| 37 | Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol. 1986;11(2):148–52 | Case series | 67 |
|
| |||
| 38 | Tan EST, Chong WS, Tey HL. Nail psoriasis: a review. Am J Clin Dermatol. 2012;13(6):375–88 | Review | 65 |
|
| |||
| 39 | Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS. Treatment of nail psoriasis: best practice recommendations from the medical board of the national psoriasis foundation. JAMA Dermatol. 2015;151(1):87–94 | Systematic 64 review | |
|
| |||
| 40 | Dawber R. Fingernail growth in normal and psoriatic subjects. Br J Dermatol. 1970:82(5):454–7 | Cohort | 64 |
|
| |||
| 41 | Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407 | RCT | 63 |
|
| |||
| 42 | Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, et al. A 24-week randomized clinical trial investigating the efficacy and safety of 2 doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–7 | RCT | 63 |
|
| |||
| 43 | Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24(5):530–4 | Cohort | 63 |
|
| |||
| 44 | Bhushan M, Moore T, Herrick AL, Griffiths CE. Nailfold video capillaroscopy in psoriasis. Br J Dermatol. 2000;142(6):1171–6 | Cohort | 63 |
|
| |||
| 45 | Gümüşel M, Özdemir M, Mevlitoǧlu Ä, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol. 2011;25(9):1080–1 | RCT | 62 |
|
| |||
| 46 | Farber EM, Nall L. Nail psoriasis. Cutis. 1992;50(3):174–8 | Review | 62 |
|
| |||
| 47 | De Jong EM, Menke HE, Van Praag MC, Van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology. 1999;199(4):313–8 | RCT | 61 |
|
| |||
| 48 | Fournie B, Viraben R, Durroux R, Lassoued S, Gay R, Fournie A. Psoriatic onycho-pachydermo-periostitis of the great toe. Anatomo-clinical study and physiopathogenic approach. Rev Rhum Mal Osteoartic. 1989;56(8–9):579–82 | Case series | 61 |
|
| |||
| 49 | Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25(5):579–86 | Cohort | 60 |
|
| |||
| 50 | Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% versus clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol. 2007;87(2):167–8 | RCT | 60 |
CME, continuing medical education; RCT, randomized controlled trial.